The Business Behind...
Health Care: Drugs
Zogenix Inc. (ZGNX: NASDAQ)
$1.52 -0.05 | -3.18%
05/21/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 44.33M | 37.58M | 23.44M | 0.00 |
| Cost of Sales | 17.23M | 17.12M | 10.68M | -5.31M |
| Gross Operating Profit | 27.09M | 20.46M | 12.76M | 5.31M |
| Selling, General, and Administrative Expenses | 49.49M | 60.46M | 51.27M | 14.10M |
| Research & Development | 21.41M | 33.04M | 28.64M | 21.44M |
| Operating Income before D & A (EBITDA) | -43.82M | -73.05M | -67.15M | -30.23M |
| Depreciation & Amortization | 3.62M | 3.38M | 3.01M | 5.31M |
| Interest Income | 53.00K | 37.00K | 5.00K | 10.00K |
| Other Income - Net | 10.31M | 119.00K | 6.61M | -1.17M |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -37.07M | -76.27M | -63.54M | -36.70M |
| Interest Expense | 10.31M | 7.64M | 10.01M | 9.19M |
| Pre-Tax Income | -47.38M | -83.91M | -73.55M | -45.89M |
| Income Taxes | 5.00K | -9.00K | 10.00K | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -47.39M | -83.90M | -73.56M | -45.89M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -47.39M | -83.90M | -73.56M | -45.89M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -47.39M | -83.90M | -73.56M | -45.89M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-47.39M | -83.90M | -73.56M | -45.89M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -47.39M | -83.90M | -73.56M | -45.89M |
| Basic EPS from Continuing Ops. | -0.59 | -1.96 | -17.63 | -4.49 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.59 | -1.96 | -17.63 | -4.49 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.59 | -1.96 | -17.63 | -4.49 |
| Basic Normalized Net Income/Share | -0.59 | -1.96 | -17.63 | -4.49 |
| EPS fr Continuing Ops. | -0.59 | -1.96 | -17.63 | -4.49 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.59 | -1.96 | -17.63 | -4.49 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.59 | -1.96 | -17.63 | -4.49 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.59 | -1.96 | -17.63 | -4.49 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with ZGNX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- UserMy stocks
- UserJaheer
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorBreakout Stocks Of The Week...
Latest ZGNX Headlines from TheStreet
- Zogenix And Battelle To Present Positive, New Data Demonstrating Value Of Needle-Free Injection For Biologics 05.20.13 | 07:05 am
- Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarin 05.10.13 | 07:05 am
- Zogenix Reports First Quarter 2013 Financial Results 05.09.13 | 04:05 pm
- Zogenix Announces Conference Call And Webcast To Present First Quarter 2013 Financial Results 05.03.13 | 07:05 am
- Zogenix Reports Positive Top-Line Results From Extended Relday(TM) Phase 1 Clinical Trial 05.02.13 | 07:05 am
- Most Profitable Second Quarter Biotech Stocks 04.02.13 | 06:04 am
- Zogenix And Battelle Extend DosePro Co-Marketing Partnership 03.27.13 | 08:03 am
- Zogenix Reports Fourth Quarter And Full Year 2012 Financial Results 03.15.13 | 07:03 am
- Zogenix Announces Conference Call And Webcast To Present Fourth Quarter And Full Year 2012 Financial Results 03.07.13 | 07:03 am
- Zogenix Provides Update On Zohydro(TM) ER Regulatory Review 02.26.13 | 08:02 pm
Press Releases for ZGNX
- DURECT Announces Positive Results From Reldayâ¿¢ Phase 1 Clinical Trial - PR Newswire 01.03.13 | 07:01 am
- Fast-Acting Migraine Treatment Highlighted During National Migraine Awareness Month - PR Newswire 06.06.11 | 08:06 am
Partner Headlines for ZGNX
- Zogenix Earnings: Here’s Why Investors are Selling Shares Now - Wall St. Cheat Sheet 05.09.13 | 07:05 am
- Zogenix Says FDA Panel Will Review Zohydro on Dec. 7th - Benzinga 11.08.12 | 09:11 am
- 3 Best Biotech Stocks For This Week (Part V) - Seeking Alpha 10.08.12 | 09:10 am
- Healthcare Business Review: Sarepta Shoots Into Outer SPACE, Roche Gets GOOD News - Wall St. Cheat Sheet 07.25.12 | 08:07 am
- Earnings Preview: Covidien - Analyst Blog - Zacks 07.23.12 | 10:07 am
- Healthcare Biz Review: Vivus' Second TRY, Intuitive Surgical's PROSPECTS - Wall St. Cheat Sheet 07.16.12 | 12:07 pm
- Benzinga's Microcap Movers for Friday July 13, 2012 - Benzinga 07.14.12 | 04:07 pm
- Company News for March 12, 2012 - Corporate Summary - Zacks 03.12.12 | 10:03 am
- Zogenix: Smart Biotech Buy Before Earnings - Seeking Alpha 03.05.12 | 07:03 am
- Nupathe's Zelrix Going Down A Path With Multiple Headwinds - Seeking Alpha 12.09.11 | 09:12 am
